Subcellular Localization of Rat CYP2E1 Impacts Metabolic Efficiency Toward Common Substrates

Overview

Journal Toxicology

Publisher Elsevier

Specialty Toxicology

Date 2015 Oct 15

PMID 26463279

Citations 10

Authors

Jessica H Hartman

H Cass Martin

Andres A Caro

Amy R Pearce

Grover P Miller

Affiliations

Soon will be listed here.

Abstract

Cytochrome P450 2E1 (CYP2E1) detoxifies or bioactivates many low molecular-weight compounds. Most knowledge about CYP2E1 activity relies on studies of the enzyme localized to endoplasmic reticulum (erCYP2E1); however, CYP2E1 undergoes transport to mitochondria (mtCYP2E1) and becomes metabolically active. We report the first comparison of in vitro steady-state kinetic profiles for erCYP2E1 and mtCYP2E1 oxidation of probe substrate 4-nitrophenol and pollutants styrene and aniline using subcellular fractions from rat liver. For all substrates, metabolic efficiency changed with substrate concentration for erCYP2E1 reflected in non-hyperbolic kinetic profiles but not for mtCYP2E1. Hyperbolic kinetic profiles for the mitochondrial enzyme were consistent with Michaelis-Menten mechanism in which metabolic efficiency was constant. By contrast, erCYP2E1 metabolism of 4-nitrophenol led to a loss of enzyme efficiency at high substrate concentrations when substrate inhibited the reaction. Similarly, aniline metabolism by erCYP2E1 demonstrated negative cooperativity as metabolic efficiency decreased with increasing substrate concentration. The opposite was observed for erCYP2E1 oxidation of styrene; the sigmoidal kinetic profile indicated increased efficiency at higher substrate concentrations. These mechanisms and CYP2E1 levels in mitochondria and endoplasmic reticulum were used to estimate the impact of CYP2E1 subcellular localization on metabolic flux of pollutants. Those models showed that erCYP2E1 mainly carries out aniline metabolism at all aniline concentrations. Conversely, mtCYP2E1 dominates styrene oxidation at low styrene concentrations and erCYP2E1 at higher concentrations. Taken together, subcellular localization of CYP2E1 results in distinctly different enzyme activities that could impact overall metabolic clearance and/or activation of substrates and thus impact the interpretation and prediction of toxicological outcomes.

Citing Articles

Subcellular expression of CYP2E1 in HepG2 cells impacts response to free oleic and palmitic acid.

Killingsworth Z, Misare K, Ryan A, Ampolini E, Mendenhall T, Engevik M Curr Res Toxicol. 2024; 7:100195.

PMID: 39429948 PMC: 11489078. DOI: 10.1016/j.crtox.2024.100195.

An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment.

Sandoval C, Calle Y, Godoy K, Farias J Int J Mol Sci. 2023; 24(7).

PMID: 37047003 PMC: 10094375. DOI: 10.3390/ijms24076031.

Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver.

Massart J, Begriche K, Hartman J, Fromenty B Cells. 2022; 11(2).

PMID: 35053404 PMC: 8774478. DOI: 10.3390/cells11020288.

Roles of Cytochrome P450 in Metabolism of Ethanol and Carcinogens.

Guengerich F, Avadhani N Adv Exp Med Biol. 2018; 1032:15-35.

PMID: 30362088 PMC: 6371814. DOI: 10.1007/978-3-319-98788-0_2.

Toxicological Implications of Mitochondrial Localization of CYP2E1.

Hartman J, Miller G, Meyer J Toxicol Res (Camb). 2017; 6(3):273-289.

PMID: 28989700 PMC: 5627779. DOI: 10.1039/C7TX00020K.

References

Robin M, Sauvage I, Grandperret T, Descatoire V, Pessayre D, Fromenty B . Ethanol increases mitochondrial cytochrome P450 2E1 in mouse liver and rat hepatocytes. FEBS Lett. 2005; 579(30):6895-902. DOI: 10.1016/j.febslet.2005.11.029. View

Real A, Hong S, Pissios P . Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab Dispos. 2013; 41(3):550-3. PMC: 3583486. DOI: 10.1124/dmd.112.049734. View

Martignoni M, Groothuis G, de Kanter R . Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006; 2(6):875-94. DOI: 10.1517/17425255.2.6.875. View

Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H . Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2006; 35(1):139-49. DOI: 10.1124/dmd.106.011932. View

Collom S, Laddusaw R, Burch A, Kuzmic P, Perry Jr M, Miller G . CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem. 2007; 283(6):3487-3496. PMC: 3933162. DOI: 10.1074/jbc.M707630200. View

Harrelson J, Atkins W, Nelson S . Multiple-ligand binding in CYP2A6: probing mechanisms of cytochrome P450 cooperativity by assessing substrate dynamics. Biochemistry. 2008; 47(9):2978-88. DOI: 10.1021/bi702020y. View

Cohen M, Leboucher G, Livnat-Levanon N, Glickman M, Weissman A . Ubiquitin-proteasome-dependent degradation of a mitofusin, a critical regulator of mitochondrial fusion. Mol Biol Cell. 2008; 19(6):2457-64. PMC: 2397313. DOI: 10.1091/mbc.e08-02-0227. View

Miller G . Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. Expert Opin Drug Metab Toxicol. 2008; 4(8):1053-64. DOI: 10.1517/17425255.4.8.1053. View

Guengerich F, Martin M, Sohl C, Cheng Q . Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat Protoc. 2009; 4(9):1245-51. PMC: 3843963. DOI: 10.1038/nprot.2009.121. View

10.

Evans M, Caldwell J . Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice. Toxicol Appl Pharmacol. 2010; 244(3):280-90. DOI: 10.1016/j.taap.2010.01.018. View

11.

Bansal S, Anandatheerthavarada H, Prabu G, Milne G, Martin M, Guengerich F . Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J Biol Chem. 2013; 288(18):12627-44. PMC: 3642310. DOI: 10.1074/jbc.M113.452367. View

12.

Hartman J, Boysen G, Miller G . Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica. 2013; 43(9):755-64. PMC: 3979932. DOI: 10.3109/00498254.2012.760764. View

13.

Hartman J, Bradley A, Laddusaw R, Perry Jr M, Miller G . Structure of pyrazole derivatives impact their affinity, stoichiometry, and cooperative interactions for CYP2E1 complexes. Arch Biochem Biophys. 2013; 537(1):12-20. PMC: 3781954. DOI: 10.1016/j.abb.2013.06.011. View

14.

Pianalto K, Hartman J, Boysen G, Miller G . Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites. Toxicol Lett. 2013; 223(2):221-7. PMC: 3831829. DOI: 10.1016/j.toxlet.2013.08.025. View

15.

Hartman J, Knott K, Miller G . CYP2E1 hydroxylation of aniline involves negative cooperativity. Biochem Pharmacol. 2013; 87(3):523-33. DOI: 10.1016/j.bcp.2013.12.003. View

16.

Hartman J, Miller G, Boysen G . Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Toxicology. 2014; 318:51-8. PMC: 4747242. DOI: 10.1016/j.tox.2014.02.003. View

17.

Levy J, Hartman J, Perry Jr M, Miller G . Structural basis for cooperative binding of azoles to CYP2E1 as interpreted through guided molecular dynamics simulations. J Mol Graph Model. 2014; 56:43-52. PMC: 4314338. DOI: 10.1016/j.jmgm.2014.11.013. View

18.

Bonanni R, Gatto M, Paci E, Gordiani A, Gherardi M, Tranfo G . Biomonitoring for Exposure Assessment to Styrene in the Fibreglass Reinforced Plastic Industry: Determinants and Interferents. Ann Occup Hyg. 2015; 59(8):1000-11. DOI: 10.1093/annhyg/mev047. View

19.

Neve E, Ingelman-Sundberg M . A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). FEBS Lett. 1999; 460(2):309-14. DOI: 10.1016/s0014-5793(99)01361-7. View

20.

Taavitsainen P, Juvonen R, Pelkonen O . In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos. 2001; 29(3):217-22. View